Sign In
Buy DSGN
$12.18
-0.440 (-3.49%)
At Close: Jul 31, 2026
Brokerages Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $15.00
01:00am, Monday, 26'th Jan 2026
Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) has received an average recommendation of "Moderate Buy" from the five analysts that are covering the firm, Marketbeat Ratings reports. One a
Design Therapeutics (NASDAQ:DSGN) Trading Down 4.5% – Here’s Why
03:38am, Friday, 02'nd Jan 2026
Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report)'s stock price traded down 4.5% during mid-day trading on Wednesday. The company traded as low as $9.43 and last traded at $9.3540. 246,384 sh
Design Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 26'th Nov 2025
CARLSBAD, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, to
The futures are trading higher after NVIDIA Inc. (NASDAQ: NVDA) blew out its fiscal third-quarter results and offered strong forward guidance, though perhaps not as robust as Wall Street had hoped.
Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1) Trials of DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs Endotheli
Design Therapeutics (NASDAQ:DSGN) Shares Up 1.6% – What’s Next?
02:38am, Tuesday, 21'st Oct 2025
Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) shot up 1.6% during trading on Monday. The stock traded as high as $5.95 and last traded at $5.83. 88,773 shares changed hands during trading
Design Therapeutics Appoints Justin Gover to Board of Directors
04:01pm, Wednesday, 10'th Sep 2025
CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, t
Design Therapeutics, Inc. (DSGN) Presents at Cantor Global Healthcare Conference 2025 Transcript
03:07am, Friday, 05'th Sep 2025
Design Therapeutics, Inc. (NASDAQ:DSGN ) Cantor Global Healthcare Conference 2025 September 4, 2025 10:55 AM EDT Company Participants Pratik Shah - Co-Founder, President, CEO, Principal Financial Offi
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
08:00am, Wednesday, 27'th Aug 2025
CARLSBAD, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, to
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results
04:01pm, Thursday, 07'th Aug 2025
Early Human Pharmacokinetics Data for DT-216P2 Demonstrates Favorable Translation from Non-Human Primates (NHPs) to Humans and Improved DT-216 Product Profile for Friedreich Ataxia (FA) Program
Initial Data from the Ongoing, Blinded Phase 1 Single-Ascending Dose Trial Has Demonstrated Favorable Safety and Pharmacokinetics IND Application Submitted to Expand RESTORE-FA Trial to U.S. Sites; No
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
08:00am, Wednesday, 28'th May 2025
CARLSBAD, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, tod
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
08:00am, Tuesday, 13'th May 2025
CARLSBAD, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, tod
Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results
04:01pm, Wednesday, 07'th May 2025
Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) Program Well-Capi
Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025 Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025
